1. Home
  2. ACIU

as 05-29-2024 11:56am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Founded: 2003 Country:
Switzerland
Switzerland
Employees: N/A City: N/A
Market Cap: 350.1M IPO Year: 2016
Target Price: $16.00 AVG Volume (30 days): 822.3K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.67 EPS Growth: N/A
52 Week Low/High: $1.90 - $5.14 Next Earning Date: 05-13-2024
Revenue: $16,819,318 Revenue Growth: 276.14%
Revenue Growth (this year): 209.08% Revenue Growth (next year): 116.11%

Share on Social Networks: